In recent years, significant progress has been made in multidimensional clinical interventions for Cardio-Kidney-Metabolic (CKM) syndrome. Professor Pan Qi from Beijing Hospital emphasizes that the core advancement lies in breaking the limitations of single-disease treatment, integrating novel medications, technological tools, and multidisciplinary collaboration to achieve a paradigm shift from disease control to systemic protection.
First, regarding novel pharmacotherapies, dual and triple receptor agonists have demonstrated multidimensional regulatory potential. Mineralocorticoid Receptor Antagonists (MRAs), such as finerenone, have achieved breakthrough progress in cardiorenal protection.
Second, in digital health management, the deep integration of artificial intelligence (AI) and wearable devices provides new approaches for dynamic monitoring and closed-loop interventions.
Third, in precision medicine, genome-guided medication precisely identifies responsive populations and adverse drug reactions. Gene-editing technologies applied to hereditary CKM offer novel strategies for individualized and targeted interventions.
Fourth, regarding upgraded Multidisciplinary Team (MDT) models, a 24-hour MDT consultation mechanism significantly shortens hospital stays for patients with newly diagnosed heart failure complicated by chronic kidney disease (CKD). Community-hospital collaborative management enables early patient identification through primary screening networks.
Finally, in lifestyle interventions, innovative paradigms such as gamified weight-loss programs and AI dietitian platforms bring new hope for comprehensive CKM management.
Currently, the core bottlenecks in CKM diagnosis and treatment stem from the complexity of multi-system interactive mechanisms and fragmented clinical management. Future breakthroughs require advancements in four key directions: multi-omics mechanistic analysis, deep AI integration, restructured MDT models, and enhanced primary care capabilities.
Specifically, establishing national biobanks to promote mechanistic research, developing AI-assisted decision support systems to optimize clinical workflows, supporting the widespread adoption of novel medications through medical insurance policies, and strengthening primary physician training and patient education are essential.
Implementing these measures will drive the transformation of CKM management from passive treatment to proactive health maintenance, ultimately reducing cardiorenal metabolic event risks and improving patient prognosis.